Back to Search
Start Over
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer
- Publication Year :
- 2019
- Publisher :
- OXFORD UNIV PRESS INC, 2019.
-
Abstract
- We retrospectively assessed association of stromal tumor-infiltrating lymphocytes (sTILs) with clinical outcomes and molecular variables reportedly predictive of trastuzumab-benefit in National Surgical Adjuvant Breast and Bowel Project B-31 (N = 2130). sTILs were assessed in 1581 eligible B-31 cases utilizing all available hematoxylin and eosin slides. Mean concordance between main reviewer and six other pathologists was 90.8% in 100 cases. Cox regressions were used to calculate hazard ratios (HRs). In chemotherapy and trastuzumab added to chemotherapy arms, increases in sTILs, as a semicontinuous variable (combined arms HR = 0.42, 95% confidence interval = 0.27 to 0.64, two-sided P
- Subjects :
- Adult
Oncology
Cancer Research
medicine.medical_specialty
Class I Phosphatidylinositol 3-Kinases
Receptor, ErbB-2
medicine.medical_treatment
H&E stain
Breast Neoplasms
Brief Communication
Disease-Free Survival
03 medical and health sciences
Lymphocytes, Tumor-Infiltrating
0302 clinical medicine
Breast cancer
Trastuzumab
Internal medicine
HER2
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
medicine
Humans
Stromal tumor
Aged
Proportional Hazards Models
030304 developmental biology
0303 health sciences
Chemotherapy
business.industry
Receptors, IgG
Hazard ratio
Middle Aged
medicine.disease
Chemotherapy regimen
Confidence interval
Pyrimidines
adjuvant trastuzumab
Chemotherapy, Adjuvant
030220 oncology & carcinogenesis
tumor-infiltrating lymphocytes
Female
prognosis
Neoplasm Recurrence, Local
Stromal Cells
business
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....02d7362165948c60e3656794381ff9a9